Related Experiment Video
Updated: May 22, 2025
07:50
Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer
Published on: September 18, 2020
5.5K
Testing Meningiomas With Methylation Arrays: Insights and Recommendations From a Large Single-Centre Study
Fernanda Ruiz1, Rossella Rispoli1,2, Zane Jaunmuktane1,3
1Division of Neuropathology, the National Hospital for Neurology and Neurosurgery, University College NHS Foundation Trust, London, UK.
Neuropathology and Applied Neurobiology
|May 13, 2025
Summary
Molecular testing helps predict meningioma recurrence risk. Grade 2 and 3 meningiomas require priority for methylation profiling, while some Grade 1 cases may also benefit.
Area of Science:
- Neuropathology
- Oncology
- Genomics
Background:
- Meningiomas are common primary central nervous system (CNS) tumors.
- Current histological grading (WHO) has limitations in predicting recurrence risk.
- Integrated molecular testing (methylation class, copy number profile) improves risk stratification.
Purpose of the Study:
- To guide prioritization for molecular testing in meningiomas.
- To understand how WHO grades correlate with molecular risk strata.
- To assess the financial viability of applying prediction algorithms broadly.
Main Methods:
- Retrospective analysis of over 1000 meningiomas.
- Utilized methylation array analysis.
- Focused on a single-center dataset.
Main Results:
- ~90% of Grade 1 meningiomas were classified as 'benign' and low-risk.
- Grade 2 meningiomas showed varied risk stratification: 39% low, 46% intermediate, 15% high.
- Grade 3 meningiomas were predominantly high-risk (74%) or intermediate-risk (26%).
Conclusions:
- Prioritize Grade 2 and 3 meningiomas for methylation profiling.
- Consider molecular analysis for a subset of Grade 1 meningiomas with potential for increased recurrence risk.
- Further research is needed for Grade 1 meningiomas with predicted higher recurrence risk.
